Damora Therapeutics is a cash-burning pre-commercial biotechnology company with below-minimum quality metrics — negative free cash flow, no competitive moat, and a 2/9 financial health score — that has reached deeply oversold conditions (RSI 15) with a volume surge suggesting potential capitulation; the 116% analyst-implied upside reflects pipeline optimism from light coverage, and the investment case depends entirely on catalyst delivery rather than current business fundamentals.
Thesis pillars
- Large Analyst Implied Upside↓Deteriorating
- Quality Well Below Investment Floor→Stable
- Capitulation Oversold Technical Setup↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Damora Therapeutics, Inc. (DMRA) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $31.48: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality.
Damora Therapeutics is a preclinical-stage biopharmaceutical company whose pipeline -- DMR-001, DMR-002, and DMR-003, all anti-mutCALR monoclonal antibodies for essential thrombocythemia and myelofibrosis -- is licensed exclusively worldwide from Paragon Therapeutics under a... Read more
Sell if holding. Engine safety override at $31.48: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Score 4.8/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, earnings proximity 23d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and SEC filing concern. Suitability: speculative.
About Damora Therapeutics, Inc.
About Damora Therapeutics, Inc.
Damora Therapeutics' lead candidate, DMR-001, is a preclinical monoclonal antibody licensed exclusively worldwide from Paragon Therapeutics to treat mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF), mutations that the company estimates drive approximately 25% of ET and 35% of MF cases in a U.S. patient population of roughly 140,000 and 20,000, respectively. The company plans to file an IND or CTA for DMR-001 in mid-2026, for DMR-002 in the second half of 2026, and for DMR-003 in 2027, all licensed under the same Paragon option agreement. Damora ended 2025 with $257.6 million in cash and equivalents after a $209.8 million net loss, following a November 2025 asset acquisition and a concurrent $285 million private placement.
As a preclinical-stage company, Damora has no products dosed in humans, no revenue, and funds development entirely through equity capital, having raised $285 million in a November 2025 private placement led by Fairmount Funds Management alongside a syndicate that included Viking Global, Wellington Management, and Andreessen Horowitz's a16z Bio + Health. Its entire mutCALR antibody portfolio -- DMR-001, DMR-002, and DMR-003 -- originates from Paragon Therapeutics under the Antibody Discovery and Option Agreement, with Paragon executing the research plan overseen by a joint development committee and Damora owing Paragon milestone payments as it exercises its license options. The company has deprioritized its legacy small-molecule assets (GB3226, GB1211, GB2064) inherited from its prior corporate structure and intends to seek partnerships or collaborations to advance them rather than fund them directly.
Show full overview
Damora's near-term valuation rests almost entirely on one unproven antibody: the 10-K states plainly that the company is substantially dependent on the success of DMR-001, and that its anticipated future clinical trials of that candidate may not succeed. Because DMR-001, DMR-002, and DMR-003 are all anti-mutCALR antibodies licensed from the same counterparty, Paragon Therapeutics, under a single option agreement, a negative Phase 1 readout for DMR-001 -- expected to begin with proof-of-concept data in mid-2027 -- would cast doubt on the entire mutCALR platform rather than being isolated to a single program, even though competitor Incyte's INCA033989 has already shown clinical proof of concept for the same biological target.
See also: Healthcare · Biotechnology
From Damora Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-20Recent Developments — Damora Therapeutics, Inc.
Latest news
- NEWS Damora Redomesticates From Delaware To Cayman Islands — benzinga Jul 17, 2026 neutral
- NEWS Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target — benzinga Jun 12, 2026 positive
- NEWS HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45 — benzinga Jun 11, 2026 positive
- NEWS Wedbush Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $35 — benzinga May 28, 2026 positive
- NEWS Damora Therapeutics Says On Track For First Regulatory Submission For DMR-001 In Mid-2026 — benzinga May 12, 2026 positive
Generated 2026-07-20T05:32:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelineDMR-00110-K Item 1A: 'We are substantially dependent on the success of DMR-001, and our anticipated future clinical trials of such product candidate may not be successful.'
- HIGHcounterpartyParagon Therapeutics (licensor)10-K Item 1: 'We have exercised our Option to license exclusive worldwide development and commercialization rights to DMR-001 from Paragon Therapeutics, Inc. ("Paragon")'
Material Events(8-K, last 90d)
- 2026-04-20Item 4.01HIGHThe Audit Committee dismissed EY Denmark as independent registered public accounting firm effective April 17, 2026, after service since 2019. EY Denmark's reports contained no adverse opinion or disagreements, though its FY2024 report included a going-concern explanatory paragraph. No successor auditor named in the excerpt.SEC filing →
- 2026-05-04Item 5.02MEDIUMEffective May 1, 2026, CFO Lori Firmani departed, receiving separation benefits under the Executive Separation Benefits Plan including full acceleration of equity awards; Brian Burkavage, SVP Finance, was appointed principal financial and accounting officer as her successor.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $31.48: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Prior stop was $29.28. Score 4.8/10, moderate confidence.
Take-profit target: $37.74 (+19.9% upside). Prior stop was $29.28. Stop-loss: $29.28.
Concentration risk — Pipeline: DMR-001; Concentration risk — Counterparty: Paragon Therapeutics (licensor); Quality below floor (1.2 < 4.0).
Damora Therapeutics, Inc. trades at a P/E of N/A (forward -15.2). TrendMatrix value score: 7.5/10. Verdict: Sell.
15 analysts cover DMRA with a consensus score of 4.3/5. Average price target: $43.
What does Damora Therapeutics, Inc. do?Damora Therapeutics is a preclinical-stage biopharmaceutical company whose pipeline -- DMR-001, DMR-002, and DMR-003,...
Damora Therapeutics is a preclinical-stage biopharmaceutical company whose pipeline -- DMR-001, DMR-002, and DMR-003, all anti-mutCALR monoclonal antibodies for essential thrombocythemia and myelofibrosis -- is licensed exclusively worldwide from Paragon Therapeutics under a single option agreement. The company has no approved products or revenue, ended 2025 with $257.6 million in cash after a $209.8 million net loss, and states that its near-term success is substantially dependent on its lead candidate, DMR-001, which it plans to file an IND for in mid-2026.